A. Aartsma-rus, A. A. Janson, W. E. Kaman, M. Bremmer-bout, G. B. Van-ommen et al., Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense, The American Journal of Human Genetics, vol.74, issue.1, pp.83-92, 2004.

F. Akdim, D. L. Tribble, J. D. Flaim, R. Yu, J. Su et al., Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia, European Heart Journal, vol.32, issue.21, pp.2650-2659, 2011.

A. Amantana and P. Iversen, Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers, Current Opinion in Pharmacology, vol.5, issue.5, pp.550-555, 2005.

C. M. Ambrose, M. P. Duyao, G. Barnes, G. P. Bates, C. S. Lin et al., Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat, Somatic Cell and Molecular Genetics, vol.20, issue.1, pp.27-38, 1994.

G. Arun, S. Diermeier, M. Akerman, K. Chang, J. E. Wilkinson et al., Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss, Genes & Development, vol.30, issue.1, pp.34-51, 2016.

D. P. Bartel, MicroRNAs: Genomics, Biogenesis, Mechanism, and Function, Cell, vol.116, issue.04, pp.45-50, 2004.

D. P. Bartel, MicroRNAs: Target recognition and regulatory functions, Cell, vol.136, issue.2, pp.215-233, 2009.

S. Benizri, A. Gissot, A. Martin, B. Vialet, M. W. Grinstaff et al., Bioconjugated oligonucleotides: Recent developments and therapeutic applications, Bioconjugate Chemistry, vol.30, pp.366-383, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02490446

M. D. Benson, M. Waddington-cruz, J. L. Berk, M. Polydefkis, P. J. Dyck et al., Inotersen treatment for patients with hereditary transthyretin amyloidosis, New England Journal of Medicine, vol.379, issue.1, pp.22-31, 2018.

C. Betts, A. F. Saleh, A. A. Arzumanov, S. M. Hammond, C. Godfrey et al., Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment, Molecular Therapy-Nucleic Acids, vol.1, 2012.

M. Binaschi, F. Zunino, and G. Capranico, Mechanism of action of DNA topoisomerase inhibitors, Stem Cells, vol.13, issue.4, pp.369-379, 1995.

. Biogen, Nusinersen. Australian Prescriber, vol.42, pp.75-76, 2019.

A. M. Blain, E. Greally, G. Mcclorey, R. Manzano, C. A. Betts et al., Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah?/?mdx mouse models of Duchenne muscular dystrophy, PLoS One, vol.13, issue.6, 2018.

J. D. Brook, M. E. Mccurrach, H. G. Harley, A. J. Buckler, D. Church et al., Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3 0 end of a transcript encoding a protein kinase family member, Cell, vol.68, issue.4, pp.799-808, 1992.

M. H. Brooke, G. M. Fenichel, R. C. Griggs, J. R. Mendell, R. Moxley et al., Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy, Neurology, vol.39, issue.4, pp.475-481, 1989.

J. S. Browning, R. M. Rice, W. V. Lee, and L. M. Baker, Gold therapy in rheumatoid arthritis, New England Journal of Medicine, vol.237, issue.12, pp.428-431, 1947.

K. M. Bushby, D. Gardner-medwin, L. V. Nicholson, M. A. Johnson, I. D. Haggerty et al., The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy, Journal of Neurology, vol.240, issue.2, pp.105-112, 1993.

K. Bushby, R. Finkel, D. J. Birnkrant, L. E. Case, P. R. Clemens et al., Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management, The Lancet Neurology, vol.9, issue.1, pp.70271-70277, 2010.

J. M. Campbell, T. A. Bacon, E. Wickstrom, M. 90084-p-cavazzana-calvo, E. Payen et al., Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid, Journal of Biochemical and Biophysical Methods, vol.20, issue.3, pp.318-322, 1990.

C. Chakraborty, A. R. Sharma, G. Sharma, C. G. Doss, and S. Lee, Therapeutic miRNA and siRNA: Moving from bench to clinic as next generation medicine, Molecular Therapy. Nucleic Acids, vol.8, pp.132-143, 2017.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved survival with Vemurafenib in melanoma with BRAF V600E mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011.

K. N. Chi, C. S. Higano, B. Blumenstein, J. M. Ferrero, J. Reeves et al., Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): A phase 3, multicentre, open-label, randomised trial, The Lancet Oncology, vol.18, issue.4, pp.30168-30175, 2017.

J. Clayton-smith and L. Laan, Angelman syndrome: A review of the clinical and genetic aspects, Journal of Medical Genetics, vol.40, issue.2, pp.87-95, 2003.

E. Cocco, M. Scaltriti, and A. Drilon, NTRK fusion-positive cancers and TRK inhibitor therapy, Nature Reviews Clinical Oncology, vol.15, issue.12, pp.731-747, 2018.

J. C. Cohen, E. Boerwinkle, T. H. Mosley, and H. H. Hobbs, Sequence variations in PCSK9, Low LDL, and protection against coronary heart disease, New England Journal of Medicine, vol.354, issue.12, pp.1264-1272, 2006.

L. H. Connors, A. Lim, T. Prokaeva, V. A. Roskens, and C. E. Costello, Tabulation of human transthyretin (TTR) variants, vol.10, pp.160-184, 2003.

J. R. Counsell, Z. Asgarian, J. Meng, V. Ferrer, C. A. Vink et al., Lentiviral vectors can be used for full-length dystrophin gene therapy, Scientific Reports, vol.7, issue.1, p.79, 2017.

S. T. Crooke, B. F. Baker, S. Xia, R. Z. Yu, N. J. Viney et al., Integrated assessment of the clinical performance of GalNAc 3 -conjugated 2 0 -O-methoxyethyl chimeric antisense oligonucleotides: I. human volunteer experience, Nucleic Acid Therapeutics, vol.29, issue.1, pp.16-32, 2019.

M. D. Disney, B. G. Dwyer, and J. L. Childs-disney, Drugging the RNA world, Cold Spring Harbor Perspectives in Biology, vol.10, issue.11, 2018.

Z. Dominski and R. Kole, Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proceedings of the National Academy of Sciences, vol.90, issue.18, pp.8673-8677, 1993.

P. Drevinek, T. Pressler, M. Cipolli, K. De-boeck, C. Schwarz et al., Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis, Journal of Cystic Fibrosis, vol.19, pp.99-107, 2019.

M. Duyao, C. Ambrose, R. Myers, A. Novelletto, F. Persichetti et al., Trinucleotide repeat length instability and age of onset in Huntington's disease, Nature Genetics, vol.4, issue.4, pp.387-392, 1993.

M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier et al., PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules, Nature, vol.365, issue.6446, pp.566-568, 1993.

A. E. Emery, Population frequencies of inherited neuromuscular diseases-A world survey, Neuromuscular Disorders, vol.1, issue.1, pp.19-29, 1991.

A. Ferlini, N. Goemans, M. Tulinius, E. H. Niks, S. Dorricott et al., T.I.2 exon skipping and PRO044 in Duchenne muscular dystrophy: Extending the program, Neuromuscular Disorders, vol.23, issue.9, p.847, 2013.

R. S. Finkel, E. Mercuri, B. T. Darras, A. M. Connolly, N. L. Kuntz et al., Nusinersen versus sham control in infantile-onset spinal muscular atrophy, New England Journal of Medicine, vol.377, issue.18, pp.1723-1732, 2017.

A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver et al., Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans, Nature, vol.391, issue.6669, pp.806-811, 1998.

K. Fitzgerald, S. White, A. Borodovsky, B. R. Bettencourt, A. Strahs et al., A highly durable RNAi therapeutic inhibitor of PCSK9, New England Journal of Medicine, vol.376, issue.1, pp.41-51, 2017.

K. M. Flanigan, D. M. Dunn, A. Von-niederhausern, P. Soltanzadeh, E. Gappmaier et al., Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort, Human Mutation, vol.30, issue.12, pp.1657-1666, 2009.

P. A. Frischmeyer and H. C. Dietz, Nonsense-mediated mRNA decayin health and disease, Human Molecular Genetics, vol.8, issue.10, pp.1893-1900, 1999.

P. J. Furdon, Z. Dominski, and R. Kole, RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds, Nucleic Acids Research, vol.17, issue.22, pp.9193-9204, 1989.

R. S. Geary, S. P. Henry, and L. R. Grillone, Fomivirsen, Clinical Pharmacokinetics, vol.41, issue.4, pp.255-260, 2002.

D. Gilot, M. Migault, L. Bachelot, F. Journé, A. Rogiers et al., A non-coding function of TYRP1 mRNA promotes melanoma growth, Nature Cell Biology, vol.19, pp.1348-1357, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01647130

A. Goyenvalle, G. Griffith, A. Babbs, S. El-andaloussi, K. Ezzat et al., Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nature Medicine, vol.21, issue.3, pp.270-275, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02407968

N. Gupta, N. Fisker, M. Asselin, M. Lindholm, C. Rosenbohm et al., A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo, PLoS One, vol.5, issue.5, 2010.

T. Gutschner, M. Hammerle, M. Eissmann, J. Hsu, Y. Kim et al., The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells, Cancer Research, vol.73, issue.3, pp.1180-1189, 2013.

P. H. Hagedorn, R. Persson, E. D. Funder, N. Albaek, S. L. Diemer et al., Locked nucleic acid: Modality, diversity, and drug discovery, Drug Discovery Today, vol.23, issue.1, pp.101-114, 2018.

H. Jahromi, A. Honda, M. Zimmerman, S. C. Spies, and M. , Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules, Nucleic Acids Research, vol.41, issue.13, pp.6687-6697, 2013.

P. Hair, F. Cameron, and K. Mckeage, Mipomersen sodium: First global approval, Drugs, vol.73, issue.5, pp.487-493, 2013.

Y. Harigaya and R. Parker, No-go decay: A quality control mechanism for RNA in translation, Wiley Interdisciplinary Reviews: RNA, vol.1, pp.132-141, 2010.

N. Heisterkamp, C. Morris, L. Sender, E. Knoppel, L. Uribe et al., Rearrangement of the human ABL oncogene in a glioblastoma, Cancer Research, vol.50, issue.11, pp.3429-3434, 1990.

D. Hong, R. Kurzrock, Y. Kim, R. Woessner, A. Younes et al., AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer, Science Translational Medicine, vol.7, issue.314, 2015.

Y. Hua, K. Sahashi, G. Hung, F. Rigo, M. A. Passini et al., Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model, Genes & Development, vol.24, issue.15, pp.1634-1644, 2010.

Y. Hua, K. Sahashi, F. Rigo, G. Hung, G. Horev et al., Peripheral SMN restoration is essential for longterm rescue of a severe spinal muscular atrophy mouse model, Nature, vol.478, issue.7367, pp.123-126, 2011.

L. Huang, A. Low, S. S. Damle, M. M. Keenan, S. Kuntz et al., Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations, Genome Biology, vol.19, issue.1, 2018.

Y. Huang, Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics, Molecular Therapy-Nucleic Acids, vol.6, pp.116-132, 2017.

M. Huarte, The emerging role of lncRNAs in cancer, Nature Medicine, vol.21, issue.11, pp.1253-1261, 2015.

H. Inoue, Y. Hayase, A. Imura, S. Iwai, K. Miura et al., Synthesis and hybridization studies on two complementary nona (2 0 -o-methyl)ribonucleotides, Nucleic Acids Research, vol.15, issue.15, pp.6131-6148, 1987.

H. L. Janssen, H. W. Reesink, E. J. Lawitz, S. Zeuzem, M. Rodriguez-torres et al., Treatment of HCV infection by targeting MicroRNA, New England Journal of Medicine, vol.368, issue.18, pp.1685-1694, 2013.

N. Jearawiriyapaisarn, H. M. Moulton, P. Sazani, R. Kole, and M. S. Willis, Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers, Cardiovascular Research, vol.85, issue.3, pp.444-453, 2010.

V. C. Jordan, Tamoxifen: A most unlikely pioneering medicine, Nature Reviews Drug Discovery, vol.2, issue.3, pp.205-213, 2003.

H. M. Kantarjian and M. Talpaz, Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias, Seminars in Oncology, vol.28, pp.9-18, 2001.

K. B. Kaufmann, H. Büning, A. Galy, A. Schambach, and M. Grez, Gene therapy on the move, EMBO Molecular Medicine, vol.5, issue.11, pp.1642-1661, 2013.

S. J. Keam, Inotersen: First global approval, Drugs, vol.78, issue.13, pp.1371-1376, 2018.

A. Khvorova and J. K. Watts, The chemical evolution of oligonucleotide therapies of clinical utility, Nature Biotechnology, vol.35, issue.3, pp.238-248, 2017.

J. Kim, C. Hu, C. M. El-achkar, L. E. Black, J. Douville et al., Patient-customized oligonucleotide therapy for a rare genetic disease, New England Journal of Medicine, vol.381, issue.17, pp.1644-1652, 2019.

Y. Kim, M. Jo, J. Schmidt, X. Luo, T. P. Prakash et al., Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular Cancer models, Molecular Therapy, vol.27, issue.9, pp.1547-1557, 2019.

H. B. Kordasiewicz, L. M. Stanek, E. V. Wancewicz, C. Mazur, M. M. Mcalonis et al., Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis, Neuron, vol.74, issue.6, pp.1031-1044, 2012.

M. Koziolkiewicz, E. Gendaszewska, M. Maszewska, C. A. Stein, W. J. Stec et al., The mononucleotidedependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5 0 -nucleotidase, Blood, vol.98, issue.4, pp.995-1002, 2001.

J. Krützfeldt, N. Rajewsky, R. Braich, K. G. Rajeev, T. Tuschl et al., Silencing of microRNAs in vivo with 'antagomirs', Nature, vol.438, issue.7068, pp.685-689, 2005.

J. Kurreck, Antisense technologies. Improvement through novel chemical modifications, European Journal of Biochemistry, vol.270, issue.8, pp.1628-1644, 2003.

R. E. Lanford, E. S. Hildebrandt-eriksen, A. Petri, R. Persson, M. Lindow et al., Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, vol.327, issue.5962, pp.198-201, 2010.

M. Langlois, N. S. Lee, J. J. Rossi, and J. Puymirat, Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts, Molecular Therapy: The Journal of the American Society of Gene Therapy, vol.7, issue.5, pp.68-74, 2003.

A. D. Lawrence, B. J. Sahakian, J. R. Hodges, A. E. Rosser, K. W. Lange et al., Executive and mnemonic functions in early Huntington's disease, Brain: A Journal of Neurology, vol.119, pp.1633-1645, 1996.

M. Lee, H. Yang, Y. Yuan, G. L'italien, and C. Chen, Epidemiology and natural history of hepatitis C virus infection, World Journal of Gastroenterology, vol.20, issue.28, pp.9270-9280, 2014.

E. Leucci, R. Vendramin, M. Spinazzi, P. Laurette, M. Fiers et al., Melanoma addiction to the long noncoding RNA SAMMSON, Nature, vol.531, issue.7595, pp.518-522, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02086933

D. Li, Q. Fu, M. Li, J. Li, C. Yin et al., Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: A meta-analysis, Future Oncology, vol.13, issue.12, pp.1115-1127, 2017.

X. H. Liang, J. G. Nichols, C. W. Hsu, T. A. Vickers, and S. T. Crooke, mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway, Nucleic Acids Research, vol.47, issue.13, pp.6900-6916, 2019.

X. H. Liang, W. Shen, H. Sun, M. T. Migawa, T. A. Vickers et al., Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames, Nature Biotechnology, vol.34, issue.8, pp.875-880, 2016.

X. Liang, H. Sun, W. Shen, S. Wang, J. Yao et al., Antisense oligonucleotides targeting translation inhibitory elements in 5 0 UTRs can selectively increase protein levels, Nucleic Acids Research, vol.45, issue.16, pp.9528-9546, 2017.

J. J. Liepnieks, L. Q. Zhang, and M. D. Benson, Progression of transthyretin amyloid neuropathy after liver transplantation, Neurology, vol.75, issue.4, pp.324-327, 2010.

H. Ling, M. Fabbri, and G. A. Calin, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nature Reviews. Drug Discovery, vol.12, issue.11, pp.847-865, 2013.

F. Liu, T. Shimakami, K. Murai, T. Shirasaki, M. Funaki et al., Efficient suppression of hepatitis C virus replication by combination treatment with miR-122 antagonism and direct-acting antivirals in cell culture systems, Scientific Reports, vol.6, issue.1, p.30939, 2016.

T. G. Lugo, A. M. Pendergast, A. J. Muller, and O. N. Witte, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products, Science, vol.247, issue.4946, pp.1079-1082, 1990.

A. M. Mabb, M. C. Judson, M. J. Zylka, and B. D. Philpot, Angelman syndrome: Insights into genomic imprinting and neurodevelopmental phenotypes, Trends in Neurosciences, vol.34, issue.6, pp.293-303, 2011.

M. Mansoor and A. J. Melendez, Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics, Gene Regulation and Systems Biology, vol.2, pp.275-295, 2008.

M. Martini, L. Vecchione, S. Siena, S. Tejpar, and A. Bardelli, Targeted therapies: How personal should we go?, Nature Reviews Clinical Oncology, vol.9, issue.2, pp.87-97, 2012.

A. G. Matera and Z. Wang, A day in the life of the spliceosome, Nature Reviews Molecular Cell Biology, vol.15, issue.2, pp.108-121, 2014.

A. L. Mccall and L. S. Farhy, Treating type 1 diabetes: From strategies for insulin delivery to dual hormonal control, Minerva Endocrinologica, vol.38, issue.2, pp.145-163, 2013.

C. C. Mello and D. Conte, Revealing the world of RNA interference, Nature, issue.7006, pp.338-342, 2004.

J. R. Mendell, N. Goemans, L. P. Lowes, L. N. Alfano, K. Berry et al., Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy, Annals of Neurology, vol.79, issue.2, pp.257-271, 2016.

L. Meng, A. J. Ward, S. Chun, C. F. Bennett, A. L. Beaudet et al., Towards a therapy for Angelman syndrome by targeting a long non-coding RNA, Nature, vol.518, issue.7539, pp.409-412, 2015.

E. Mercuri, B. T. Darras, C. A. Chiriboga, J. W. Day, C. Campbell et al., Nusinersen versus sham control in later-onset spinal muscular atrophy, New England Journal of Medicine, vol.378, issue.7, pp.625-635, 2018.

A. Messina, F. Langlet, K. Chachlaki, J. Roa, S. Rasika et al., A microRNA switch regulates the rise in hypothalamic GnRH production before puberty, Nature Neuroscience, vol.19, issue.6, pp.835-844, 2016.

M. Migault, E. Donnou-fournet, M. Galibert, and D. Gilot, Definition and identification of small RNA sponges: Focus on miRNA sequestration, Methods, vol.117, pp.35-47, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01502131

H. I. Miller, A. D. Riggs, and G. N. Gill, Ribonuclease H (hybrid) in Escherichia coli. Identification and characterization, The Journal of Biological Chemistry, vol.248, issue.7, pp.2621-2624, 1973.

A. P. Monaco, C. J. Bertelson, S. Liechti-gallati, H. Moser, and L. M. Kunkel, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, vol.2, issue.1, pp.90-95, 1988.

B. P. Monia, E. A. Lesnik, C. Gonzalez, W. F. Lima, D. Mcgee et al., Evaluation of 2 0 -modified oligonucleotides containing 2 0 -deoxy gaps as antisense inhibitors of gene expression, The Journal of Biological Chemistry, vol.268, issue.19, pp.14514-14522, 1993.

S. A. Mulders, W. J. Van-den-broek, T. M. Wheeler, H. J. Croes, P. Van-kuik-romeijn et al., Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy, Proceedings of the National Academy of Sciences, vol.106, issue.33, pp.13915-13920, 2009.

F. Muntoni, S. Torelli, and A. Ferlini, Dystrophin and mutations: One gene, several proteins, multiple phenotypes. The Lancet Neurology, vol.2, pp.731-740, 2003.

C. Napoli, C. Lemieux, and R. Jorgensen, Introduction of a chimeric Chalcone synthase gene into Petunia results in reversible cosuppression of homologous genes in trans, The Plant Cell, vol.2, issue.4, pp.279-289, 1990.

A. Nicolussi, S. D'inzeo, C. Capalbo, G. Giannini, and A. Coppa, The role of peroxiredoxins in cancer, Molecular and Clinical Oncology, vol.6, issue.2, pp.139-153, 2017.

P. Nielsen, M. Egholm, R. Berg, and O. Buchardt, Sequence-selective recognition of DNA by strand displacement with a thyminesubstituted polyamide, Science, vol.254, issue.5037, pp.1497-1500, 1991.

D. M. Noll, T. M. Mason, and P. S. Miller, Formation and repair of Interstrand cross-links in DNA, Chemical Reviews, vol.106, issue.2, pp.277-301, 2006.

S. Odate, V. Veschi, S. Yan, N. Lam, R. Woessner et al., Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity, Clinical Cancer Research, vol.23, issue.7, pp.1771-1784, 2017.

J. P. Orengo, P. Chambon, D. Metzger, D. R. Mosier, G. J. Snipes et al., Expanded CTG repeats within the DMPK 3 0 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy, Proceedings of the National Academy of Sciences, vol.105, issue.7, pp.2646-2651, 2008.

G. Pelaia, W. Canonica, A. Matucci, R. Paolini, M. Triggiani et al., Targeted therapy in severe asthma today: Focus on immunoglobulin E. Drug Design, Development and Therapy, vol.11, 1979.

C. M. Perry and J. A. Balfour, Fomivirsen. Drugs, vol.57, issue.3, pp.375-380, 1999.

J. A. Phillips, S. J. Craig, D. Bayley, R. A. Christian, R. Geary et al., Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration, Biochemical Pharmacology, vol.54, issue.6, pp.657-668, 1997.

D. P. Potaczek, H. Garn, S. D. Unger, and H. Renz, Antisense molecules: A new class of drugs, Journal of Allergy and Clinical Immunology, vol.137, issue.5, pp.1334-1346, 2016.

T. P. Prakash, M. J. Graham, J. Yu, R. Carty, A. Low et al., Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice, Nucleic Acids Research, vol.42, issue.13, pp.8796-8807, 2014.

T. P. Prakash, A. E. Mullick, R. G. Lee, J. Yu, S. T. Yeh et al., Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle, Nucleic Acids Research, vol.47, issue.12, pp.6029-6044, 2019.

F. J. Raal, R. D. Santos, D. J. Blom, A. D. Marais, M. Charng et al., Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial, The Lancet, vol.375, issue.9719, pp.998-1006, 2010.

S. Rabinovitz, Y. Kaufman, G. Ludwig, A. Razin, and R. Shemer, Mechanisms of activation of the paternally expressed genes by the Prader-Willi imprinting center in the Prader-Willi/Angelman syndromes domains, Proceedings of the National Academy of Sciences of the United States of America, vol.109, pp.7403-7408, 2012.

K. K. Ray, U. Landmesser, L. A. Leiter, D. Kallend, R. Dufour et al., Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol, New England Journal of Medicine, vol.376, issue.15, pp.1430-1440, 2017.

M. J. Reilley, P. Mccoon, C. Cook, P. Lyne, R. Kurzrock et al., STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial, Journal for Immunotherapy of Cancer, vol.6, issue.1, p.119, 2018.

D. Renneberg, E. Bouliong, U. Reber, D. Schümperli, and C. J. Leumann, Antisense properties of tricyclo-DNA, Nucleic Acids Research, vol.30, issue.13, pp.2751-2757, 2002.

D. N. Ricotta and W. Frishman, Mipomersen, Cardiology in Review, vol.20, issue.2, pp.1-95, 2012.

C. Rinaldi and M. J. Wood, Antisense oligonucleotides: The next frontier for treatment of neurological disorders, Nature Reviews Neurology, vol.14, issue.1, pp.9-21, 2017.

B. Roehr, Fomivirsen approved for CMV retinitis, Journal of the International Association of Physicians in AIDS Care, vol.4, issue.10, pp.14-16, 1998.

J. E. Rosenberg, P. H. O'donnell, A. V. Balar, B. A. Mcgregor, E. I. Heath et al., Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy, Journal of Clinical Oncology, vol.37, pp.2592-2600, 2019.

J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin et al., The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine, The Oncologist, vol.14, issue.4, pp.320-368, 2009.

J. D. Rowley, A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by Quinacrine fluorescence and Giemsa staining, Nature, issue.5405, pp.290-293, 1973.

C. M. Rudin, J. T. Poirier, L. A. Byers, C. Dive, A. Dowlati et al., Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data, Nature Reviews Cancer, vol.19, issue.5, pp.289-297, 2019.

R. Rupaimoole and F. J. Slack, MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases, Nature Reviews Drug Discovery, vol.16, issue.3, pp.203-222, 2017.

R. D. Santos, F. J. Raal, A. L. Catapano, J. L. Witztum, E. Steinhagen-thiessen et al., Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.35, issue.3, pp.689-699, 2015.

I. Sermet-gaudelus, J. P. Clancy, D. P. Nichols, J. A. Nick, K. De-boeck et al., Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis, Journal of Cystic Fibrosis, vol.18, issue.4, pp.536-542, 2019.

L. X. Shen, E. R. Kandimalla, and S. Agrawal, Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H, Bioorganic & Medicinal Chemistry, vol.6, issue.10, p.131, 1998.

W. Shen, C. L. De-hoyos, M. T. Migawa, T. A. Vickers, H. Sun et al., Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index, Nature Biotechnology, vol.37, issue.6, pp.640-650, 2019.

M. Shimojo, A. J. Paquette, D. J. Anderson, and L. B. Hersh, Protein kinase a regulates cholinergic gene expression in PC12 cells: REST4 silences the silencing activity of neuron-restrictive silencer factor/REST, Molecular and Cellular Biology, vol.19, issue.10, pp.6788-6795, 1999.

M. Shimojo, Y. Kasahara, M. Inoue, S. Tsunoda, Y. Shudo et al., A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer, Scientific Reports, vol.9, issue.1, 2019.

D. Sienkiewicz, B. Okurowska-zawada, G. Paszko-patej, K. Kawnik, and W. Kulak, Duchenne muscular dystrophy: Current cell therapies, Therapeutic Advances in Neurological Disorders, vol.8, pp.166-177, 2015.

F. Skoulidis and J. V. Heymach, Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy, Nature Reviews Cancer, vol.19, issue.9, pp.495-509, 2019.

J. Song, S. K. Smith, G. J. Hannon, and L. Joshua-tor, Crystal structure of argonaute and its implications for RISC slicer activity, Science, issue.5689, pp.1434-1437, 2004.

R. Steffens and C. J. Leumann, Tricyclo-DNA: A phosphodiester-backbone based DNA analog exhibiting strong complementary basepairing properties, Journal of American Chemical Society, vol.119, pp.11548-11549, 1997.

C. A. Stein, C. Subasinghe, K. Shinozuka, and J. S. Cohen, Physicochemical properties of phosphorothioate oligodeoxynucleotides, Nucleic Acids Research, vol.16, issue.8, pp.3209-3221, 1988.

J. Stenvang, A. Petri, M. Lindow, S. Obad, and S. Kauppinen, Inhibition of microRNA function by antimiR oligonucleotides, Silence, vol.3, issue.1, 2012.

M. L. Stephenson and P. C. Zamecnik, Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proceedings of the National Academy of Sciences of the United States of America, vol.75, pp.285-288, 1978.

K. Takakura, A. Kawamura, Y. Torisu, S. Koido, N. Yahagi et al., Clinical potential of oligonucleotide therapeutics against pancreatic cancer, International Journal of Molecular Sciences, vol.20, p.3331, 2019.

M. Tanowitz, L. Hettrick, A. Revenko, G. A. Kinberger, T. P. Prakash et al., Asialoglycoprotein receptor 1 mediates productive uptake of N-Acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes, Nucleic Acids Research, vol.45, issue.21, pp.12388-12400, 2017.

A. A. Thompson, M. C. Walters, J. Kwiatkowski, J. E. Rasko, J. Ribeil et al., Gene therapy in patients with transfusion-dependent ?-thalassemia, New England Journal of Medicine, vol.378, issue.16, pp.1479-1493, 2018.

S. Tsimikas, E. Karwatowska-prokopczuk, I. Gouni-berthold, J. C. Tardif, S. J. Baum et al., , 2020.

, Lipoprotein(a) reduction in persons with cardiovascular disease, The New England Journal of Medicine, vol.382, issue.3, pp.244-255

M. H. Van-der-ree, A. J. Van-der-meer, A. C. Van-nuenen, J. De-bruijne, S. Ottosen et al., Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma, Alimentary Pharmacology and Therapeutics, vol.43, issue.1, pp.102-113, 2016.

J. C. Van-deutekom, A. A. Janson, I. B. Ginjaar, W. S. Frankhuizen, A. Aartsma-rus et al., Local dystrophin restoration with antisense oligonucleotide PRO051, New England Journal of Medicine, vol.357, issue.26, pp.2677-2686, 2007.

J. C. Van-deutekom, M. Bremmer-bout, A. A. Janson, I. B. Ginjaar, F. Baas et al., Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Human Molecular Genetics, vol.10, issue.15, pp.1547-1554, 2001.

R. N. Veedu and J. Wengel, Locked nucleic acid as a novel class of therapeutic agents, RNA Biology, vol.6, issue.3, pp.321-323, 2009.

, A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS, American Journal of Ophthalmology, vol.133, issue.4, pp.1327-1329, 2002.

W. Wang, C. Han, Y. Sun, T. Chen, and Y. Chen, Noncoding RNAs in cancer therapy resistance and targeted drug development, Journal of Hematology & Oncology, vol.12, issue.1, 2019.

T. F. Westbrook, E. S. Martin, M. R. Schlabach, Y. Leng, A. C. Liang et al., A genetic screen for candidate tumor suppressors identifies REST, Cell, vol.121, issue.6, pp.837-848, 2005.

T. M. Wheeler, A. J. Leger, S. K. Pandey, A. R. Macleod, M. Nakamori et al., Targeting nuclear RNA for in vivo correction of myotonic dystrophy, Nature, vol.488, issue.7409, pp.111-115, 2012.

X. Zhang, S. Wang, H. Wang, J. Cao, X. Huang et al., Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway, Molecular Cancer, vol.18, issue.1, p.20, 2019.

Y. Zhang, C. Ge, C. Zhu, and K. Salaita, DNA-based digital tension probes reveal integrin forces during early cell adhesion, Nature Communications, vol.5, issue.1, 2014.

A. M. Quemener, L. Bachelot, A. Forestier, E. Donnou-fournet, D. Gilot et al., The powerful world of antisense oligonucleotides: From bench to bedside, WIREs RNA, 1594.
URL : https://hal.archives-ouvertes.fr/hal-02565099